Trade Summary

4 days ago, Valantine Hannah, serving as Dir at BridgeBio Pharma, Inc. (BBIO), sold 5,004 shares at $68.25 per share, for a total transaction value of $341,523.72. Following this transaction, Valantine Hannah now holds 9,259 shares of BBIO.

This sale represents a 35.08% decrease in Valantine Hannah's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 22, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 24, 2026 at 6:06 PM ET, 2 days after the trade was made.

BridgeBio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.